Prospective Double-Blind Study of Zidovudine in Early Stage HIV infection
Final rept. 23 Sep 1987-22 Sep 1991,
FITZSIMONS ARMY MEDICAL CENTER AURORA CO
Pagination or Media Count:
Data was collected from Denver Health and Hospital civilian patients and FAMC military patients with early HIV infection randomized to either Zidovudine or placebo at 800mgday. Because of the salutary response to 12- 1500mg of Zidovudineday in patients treated above 200 CD4 helper cellsmcL in the early phase 2 studies, it was thought that the time to begin ZDV was when patients were between 2-500 helper cells and had at least one symptom usually lymphadenopathy. Thus they were DOD class 2-5 persons. Although this study did not achieve the statistical significance for progression to severe ARCADS of the larger NIH studies or the VARAD1WRAMc study, it provided a significant portion of the data for Zidovudine safety at 5-800mgday and showed a very delimited trend toward retardation of DOD class progression which is important and preservation of health of the soldier, dependents and retired DOD health care beneficiaries. The study does further validate ZDVs effect on surrogate markers.